Home/Race Oncology/Dr. David Fuller
DD

Dr. David Fuller

Non-Executive Chairman

Race Oncology

Therapeutic Areas

Race Oncology Pipeline

DrugIndicationPhase
Bisantrene (RC220)Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 2